喜保宁功效与作用

Vigabatrin Sabril is an irreversible GABA transaminase inhibitor that can increase the level of GABA in the brain and cerebrospinal fluid. In August 2009, Vigabatrin Sabril was approved for marketing in the United States. On January 16, 2019, the FDA approved the marketing of a generic version of Vigabatrin Sabril. The indications of Vigabatrin Sabril include: adjuvant treatment of anti-epilepsy; Vigabatrin Sabril can be used as an auxiliary treatment for partial seizures of refractory complex epilepsy; Vigabatrin Sabril can also be used to treat infantile spasms and Lennox-Gastaut syndrome; Vigabatrin Sabril can be used for tardive dyskinesia. Sabril is the drug of choice for Tsc epilepsy in foreign countries. In terms of controlling Tsc epileptic seizures, about 95% of children have a good response to Vigabatrin Sabril. Once an epileptic seizure is discovered, regardless of form, Vigabatrin Sabril can be the first choice, and the effect is better when used for the first time. Especially for infantile spasms (peak arrhythmia on the electroencephalogram), Vigabatrin Sabril should be taken as soon as possible.

Vigabatrin tablets Sabril can be used as an auxiliary treatment for patients who are ineffective with other anti-epileptic drugs, and can also be used to treat patients with partial seizures (mainly used to control complex partial seizures). Sabril is also effective in infants with West syndrome (infant spasms), a condition in which conventional antiepileptic drugs are generally ineffective.

Experimental method: 10 children with TSC and IS who were treated with vigabatrin tablets Sabril from February 2013 to July 2015 were collected, their treatment conditions were retrospectively analyzed, and their clinical efficacy and adverse reactions were observed. Results The cumulative time of using vigabatrin tablets Sabril in this group ranged from 1 to 49 months, with a median time of 10 months. After diagnosis, 2 cases were treated with vigabatrin tablets Sabril as the first choice, and vigabatrin tablets Sabril were added after other drug treatments were not satisfactory. Among them, 8 cases of spasm disappeared or were close to disappearing, 1 case did not improve, and 1 case improved after adding adrenocorticotropic hormone. 6 cases took effect within 1 week, 1 case took effect on 15 days and 60 days respectively, and the average onset of effect was 5 days. The drug was well tolerated in 10 cases and the adverse reactions were mild. The trial conclusion shows that vigabatrin tablet Sabril has a good effect in the treatment of tuberous sclerosis and infantile spasms. It has a quick onset of action and good tolerability, and can be used as a first-line treatment drug.

To be alert, Sabril can cause permanent vision loss in infants, children, and adults, including progressive and permanent bilateral concentric visual field constriction in >30% of patients, ranging in severity from mild to severe, including tunnel vision to visual acuity fixed within 10 degrees, and can result in disability.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician. 

Recommended hot articles: